64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

Article Properties
  • Language
    English
  • DOI (url)
    10.2967/jnumed.112.118612
  • Publication Date
    2013/09/12
  • Journal
    Journal of Nuclear Medicine
  • Indian UGC (journal)
  • Refrences
    30
  • Citations
    201
  • Kenji Tamura
  • Hiroaki Kurihara
  • Kan Yonemori
  • Hitoshi Tsuda
  • Junko Suzuki
  • Yuzuru Kono
  • Natsuki Honda
  • Makoto Kodaira
  • Harukaze Yamamoto
  • Mayu Yunokawa
  • Chikako Shimizu
  • Koki Hasegawa
  • Yousuke Kanayama
  • Satoshi Nozaki
  • Takayuki Kinoshita
  • Yasuhiro Wada
  • Shusaku Tazawa
  • Kazuhiro Takahashi
  • Yasuyoshi Watanabe
  • Yasuhiro Fujiwara
Cite
Tamura, Kenji, et al. “64Cu-DOTA-Trastuzumab PET Imaging in Patients With HER2-Positive Breast Cancer”. Journal of Nuclear Medicine, vol. 54, no. 11, 2013, pp. 1869-75, https://doi.org/10.2967/jnumed.112.118612.
Tamura, K., Kurihara, H., Yonemori, K., Tsuda, H., Suzuki, J., Kono, Y., Honda, N., Kodaira, M., Yamamoto, H., Yunokawa, M., Shimizu, C., Hasegawa, K., Kanayama, Y., Nozaki, S., Kinoshita, T., Wada, Y., Tazawa, S., Takahashi, K., Watanabe, Y., & Fujiwara, Y. (2013). 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer. Journal of Nuclear Medicine, 54(11), 1869-1875. https://doi.org/10.2967/jnumed.112.118612
Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, et al. 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer. Journal of Nuclear Medicine. 2013;54(11):1869-75.
Journal Categories
Medicine
Medicine (General)
Medicine
Medicine (General)
Medical physics
Medical radiology
Nuclear medicine
You May Also Like
Refrences
Title Journal Journal Categories Citations Publication Date
Human dosimetry and tumor kinetics of 111In CHX-A” DTPA trastuzumab in solid tumors using gamma-camera imaging [abstract] 2011
Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0 2006
OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine 2005
HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis Breast Cancer Research and Treatment
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
 82 2011
Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment Annals of Oncology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 29 2011
Citations
Title Journal Journal Categories Citations Publication Date
Nanomedicine Tumor Targeting

 Advanced Materials
  • Science: Chemistry: General. Including alchemy
  • Science: Chemistry: Physical and theoretical chemistry
  • Technology: Chemical technology
  • Science: Chemistry
  • Science: Physics
  • Science: Physics
  • Technology: Electrical engineering. Electronics. Nuclear engineering: Materials of engineering and construction. Mechanics of materials
  • Technology: Electrical engineering. Electronics. Nuclear engineering: Materials of engineering and construction. Mechanics of materials
 1 2024
Formulation of patient dose of [177Lu]Lu‐Trastuzumab using in‐house developed freeze‐dried kit: A path forward for clinical translation

 Journal of Labelled Compounds and Radiopharmaceuticals
  • Science: Chemistry: Organic chemistry: Biochemistry
  • Medicine: Therapeutics. Pharmacology
  • Science: Chemistry: Analytical chemistry
  • Science: Chemistry: Analytical chemistry
  • Science: Chemistry: Inorganic chemistry
  • Science: Physics: Nuclear and particle physics. Atomic energy. Radioactivity
  • Science: Chemistry
 2024
Molecular probes targeting HER2 PET/CT and their application in advanced breast cancer

 Journal of Cancer Research and Clinical Oncology
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
 2024
Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancer

 Neuro-Oncology
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
 2024
Approaches to Reducing Normal Tissue Radiation from Radiolabeled Antibodies

 Pharmaceuticals
  • Medicine: Pharmacy and materia medica
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Public aspects of medicine: Toxicology. Poisons
 2024
Citations Analysis
Category Category Repetition
Medicine: Medicine (General)92
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens47
Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine41
Science: Chemistry35
Medicine: Therapeutics. Pharmacology30
Science: Biology (General)25
Science: Chemistry: General. Including alchemy24
Medicine: Public aspects of medicine: Toxicology. Poisons20
Science: Chemistry: Analytical chemistry14
Science: Chemistry: Organic chemistry: Biochemistry13
Medicine: Internal medicine10
Science: Chemistry: Organic chemistry9
Science: Chemistry: Inorganic chemistry9
Science: Physics: Nuclear and particle physics. Atomic energy. Radioactivity7
Medicine6
Science: Physics5
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy5
Science: Science (General)4
Medicine: Medicine (General): Medical technology4
Technology: Electrical engineering. Electronics. Nuclear engineering: Materials of engineering and construction. Mechanics of materials4
Science: Biology (General): Cytology4
Science: Biology (General): Genetics4
Medicine: Pharmacy and materia medica4
Technology: Electrical engineering. Electronics. Nuclear engineering: Nuclear engineering. Atomic power3
Science3
Science: Chemistry: Physical and theoretical chemistry3
Technology: Chemical technology3
Medicine: Surgery3
Technology: Chemical technology: Biotechnology2
Medicine: Gynecology and obstetrics2
Medicine: Pathology2
Technology: Chemical technology: Polymers and polymer manufacture1
Medicine: Public aspects of medicine1
Medicine: Nursing1
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system1
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system1
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology1
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system1
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry1
Technology1
The category Medicine: Medicine (General) 92 is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Current status and perspective of targeted radionuclide therapy for cancer and was published in 2014. The most recent citation comes from a 2024 study titled Approaches to Reducing Normal Tissue Radiation from Radiolabeled Antibodies. This article reached its peak citation in 2023, with 25 citations. It has been cited in 130 different journals, 20% of which are open access. Among related journals, the Cancers cited this research the most, with 8 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year